Travere Therapeutics (TVTX) News
NASDAQ: TVTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
47.00-1.30 (-2.69%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
TVTX news summary
We found 9 recent headlines mentioning Travere Therapeutics (TVTX): 0 in the past week and 6 in the past 30 days, most often from Nasdaq, Seeking Alpha, Business Wire. For price context, TVTX is down 2.69% at $47.00. The most recent story, "Why is Travere Therapeutics stock sliding today?", was published by Investing.com on Nov 3, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Travere Therapeutics headlines
- Why is Travere Therapeutics stock sliding today?Investing.com
- Travere (TVTX) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaq
- Travere Therapeutics Non-GAAP EPS of -$0.31 misses by $0.73, revenue of $224.5M beats by $29.21MSeeking Alpha
- Travere Therapeutics Reports Third Quarter 2026 Financial ResultsSAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today reported its third quarter 2026 financial results and provided a corporate update. “Strong execution across our…Business Wire
- Travere Therapeutics Q3 2026 Earnings PreviewSeeking Alpha
- Travere Therapeutics to Report Third Quarter 2026 Financial ResultsSAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced it will report third quarter 2026 financial results on Monday, November 2, 2026, after the close of the…Business Wire
- AstraZeneca Gets Accelerated FDA Nod for Ultomiris in IgA NephropathyAZN wins accelerated FDA approval for Ultomiris in IgA nephropathy, marking the fifth approved indication for the drug in the United States.NasdaqAZN, NVS, TVTX
- Biotech Stocks At 52-Week Highs - TXG, OBIO, AVAH, OSCR, LFST, TVTX(RTTNews) - The biotech stocks listed below reached a new 52-week high on September 11, 2026, owing to upcoming clinical readouts and positive financial results. 10x Genomics Inc. (TXG) 10x Genomics…NasdaqAVAH, LFST, OBIO, OSCR
- Biotech Stocks At 52-Week Highs - OBIO, AVAH, TVTX, TXG, LFST(RTTNews) - The following biotech stocks reached a 52-week high on September 10, 2026, driven by significant clinical developments or financial progress. Orchestra BioMed Holdings Inc. (OBIO)…NasdaqAVAH, LFST, OBIO, TVTX